| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine [R. T. D., D. S. A., J. D. L.] and Radiology [G. T. B.], Cancer Center Division, The University of Arizona, Tucson, Arizona 85724
The antitumor antibiotic mitomycin C (MMC) was studied in vitro using L1210 leukemia and 8226 human myeloma cells. Cytotoxicity was evaluated by colony formation in soft agar, and DNA damage was analyzed using alkaline elution filter assays. The purposes of these studies were: (a) to characterize the time course of MMC-DNA damage; (b) to characterize the type of DNA damage [DNA-DNA interstrand cross-links (ISC), DNA-protein cross-links (DPC), single and double strand breaks (SSBs, DSBs)]; and (c) to correlate this damage with cytotoxicity in vitro. Colony-forming assays showed the D0 value for 1 h MMC to be 15.0 µM for L1210 cells and 17 µM for 8226 cells. Alkaline elution studies showed that dose-dependent ISCs and DPCs formed rapidly following MMC exposure. Removal of cross-links was delayed, with only 50% repaired 32 h after exposure. There was a good correlation between ISCs and cytotoxicity in dose-response studies in each cell line. ISCs appeared to comprise most of the MMC-DNA lesions in both cell lines. No DNA SSBs or DSBs were observed following MMC exposure. Nuclei isolated from both cell lines and exposed to MMC produced less MMC alkylation than whole cells but, again, no strand breaks were evident. These results demonstrate that MMC is principally an alkylating agent when used at pharmacological (cytotoxic) concentrations in vitro. The lack of evidence for DNA strand breaks discounts a significant role for putative quinone-generated oxygen free radicals in the production of MMC cytotoxicity.
1 Supported in part by Grants CA 23074, CA 17094, CA 26972, and CA 17343 from the National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, MD 20205.
Presented in part at the Seventy-fifth Annual Meeting of the American Association for Cancer Research, May 10, 1984, Toronto, Canada (14).
2 To whom requests for reprints should be addressed, at Cancer Center, Arizona Health Sciences Center, 1501 N. Campbell Avenue, Tucson, AZ 85724.
Received 12/14/84. Revised 4/24/85. Accepted 4/26/85.
This article has been cited by other articles:
![]() |
J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, and Y.-W. Lin Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Carcinogenesis, July 1, 2008; 29(7): 1448 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. I. Abdel-Halim, A. T. Natarajan, L. H. F. Mullenders, and J. J. W. A. Boei Mitomycin C-induced pairing of heterochromatin reflects initiation of DNA repair and chromatid exchange formation J. Cell Sci., April 15, 2005; 118(8): 1757 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ochs, R. W. Sobol, S. H. Wilson, and B. Kaina Cells Deficient in DNA Polymerase {beta} Are Hypersensitive to Alkylating Agent-induced Apoptosis and Chromosomal Breakage Cancer Res., April 1, 1999; 59(7): 1544 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Dorr and J. D. Liddil Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids Journal of Oncology Pharmacy Practice, January 1, 1995; 1(3): 19 - 24. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |